2021
DOI: 10.1186/s42358-021-00217-0
| View full text |Cite
|
Sign up to set email alerts
|

Abstract: Background There is a lack of information on the role of chronic use of hydroxychloroquine during the SARS-CoV-2 outbreak. Our aim was to compare the occurrence of COVID-19 between rheumatic disease patients on hydroxychloroquine with individuals from the same household not taking the drug during the first 8 weeks of community viral transmission in Brazil. Methods This baseline cross-sectional analysis is part of a 24-week observational multi-cent… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
6
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 5 publications
(6 citation statements)
references
References 82 publications
(84 reference statements)
0
6
0
Order By: Relevance
“…Multiple studies across the globe have failed to demonstrate a significant reduction in the SARS-CoV-2 infection in SLE patients who are on long-term HCQ therapy. 15 17 Furthermore, in a large population-based survey involving more than 26,000 patients of lupus in the UK, HCQ did not influence the mortality due to COVID-19. 18 …”
Section: Discussionmentioning
confidence: 92%
“…Multiple studies across the globe have failed to demonstrate a significant reduction in the SARS-CoV-2 infection in SLE patients who are on long-term HCQ therapy. 15 17 Furthermore, in a large population-based survey involving more than 26,000 patients of lupus in the UK, HCQ did not influence the mortality due to COVID-19. 18 …”
Section: Discussionmentioning
confidence: 92%
“…As the drug most frequently appearing in the control group of included studies, HCQ was initially applied to the treatment of COVID-19 because of its potential benefit of attenuating the cytokine storm observed in moderate or severe COVID-19 forms and mitigating unfavorable outcomes, however, there is controversy regarding its efficacy and safety in the treatment of patients with COVID-19 [ 49 ]. Several studies have demonstrated that HCQ and azithromycin, alone or in combination, prolong the QTc interval, which can easily lead to myocarditis, a very common complication after infection with SARS-CoV-2 [ 50–54 ].…”
Section: Discussionmentioning
confidence: 99%
“…abatacept), IL-6 inhibitors, and non-steroidal anti-inflammatory drugs presented a similar occurrence and outcome of COVID-19 as occurred with the controls. Regarding hydroxychloroquine, the risk of adverse reactions increases when doses are higher than usual in hospitalized COVID-19 patients [ 102 ]. Regarding Jak-inhibitors, conflicting results have been reported, which may be related to the dual effect of Jak-inhibitors in controlling both the innate immune response and the cytokine storm associated with severe COVID-19 [ 103 ].…”
Section: Sars-cov-2/covid19 Vaccination and Autoimmune And Chronic In...mentioning
confidence: 99%